ECONOMIC ASPECTS OF INDIVIDUAL TREATMENT IN POLAND—OUT-PATIENT VIEWPOINT

Czech M1, Horoszweska M2, Pachocki R1
1Server Polska, Warsaw, Poland; 2Warsaw University of Technology, Warsaw, Poland

Fast and dynamic development of medicine and pharmacy is linked not only with efficacy and safety of drugs but also with their cost-effectiveness, especially when patients’ co-payment systematically increases. OBJECTIVES: To investigate the recognition of the term “pharmacoeconomics” by patients of an open pharmacy and the role of economic aspects in decision making concerning drug purchases. METHODS: A total of 270 patients (170 suffering from chronic and 100 from acute diseases) were interviewed (18 questions with a 5 level weighted / validity scale). RESULTS: A total of 67% of respondents were able to define (more or less precisely) the term “pharmacoeconomics”. Thirty percent (30%) of patients treated acutely and eight 8% chronically were unable to pay for their prescriptions (level of co-payment too high), which decreases their compliance (different factors also apply). Price elasticity of demand was low: 67 out of 100 treated chronically and 76 out of 100 treated acutely would not have a prescription made up if the price of a drug increased by 50%. On the other hand, 88% and 92% of patients treated for chronic and acute diseases respectively would find sources of finance if non-treatment led to serious health consequences and 93% of respondents would pay more for a drug if they were sure it was absolutely safe. Forty percent (40%) of respondents declared that they would like to use only drugs which make them able to work, 81% prefer to take effective but sometimes expensive drugs in order to shorten hospitalization time. CONCLUSIONS: Elements of cost-effectiveness, relationship between the price of a drug and its effectiveness and safety as well as different cost components linked to a medical condition remain within the scope of interest of patients purchasing drugs in pharmacy.

PREFERENCES MATTER: UNDERSTANDING DEMAND FOR VOLUNTARY HEALTH INSURANCE

De Allegri M1, Sanon M2, Bridges JFP1, Sauerborn R1
1University of Heidelberg, Heidelberg, Germany; 2Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso

OBJECTIVES: The aim of this study was to explore individual and community factors affecting the decision making process leading to purchase of voluntary health insurance among a rural community in sub-Saharan Africa. Such intervention is crucial in the context given that, by pooling resources and risks across a community, it can increase equitable access to health care services and reduce health disparities. METHODS: The study used qualitative research methods to understand consumers’ preferences in relation to their decision to purchase voluntary health insurance. This approach was considered preferable to quantitative methods traditionally used in demand analysis because of its potential to capture the complexity involved. Thirty-two respondents were selected for an individual in-depth interview using a stratified sampling design based on insurance status, distance to health facility and socio-economic status. All interviews were tape recorded, fully translated and transcribed, analyzed and triangulated by two independent researchers using Atlas.ti software. Data from eight focus group discussions provided an additional valuable source of triangulation. RESULTS: Participants, regardless of insurance status, understood the insurance potential to decrease health inequalities by facilitating access to Health Care services. They justified their decision to purchase or not to purchase insurance in relation to their preference regarding specific elements of the scheme, including the enrollment unit, the benefit package, the management structure, the payment modalities, and the timing of the enrollment campaign. CONCLUSIONS: The use of qualitative methods led to a thorough investigation of consumers’ preferences. It allowed to formulate clear and concise policy recommendations to be used to redirect the scheme design. The qualitative approach proved to be a valuable tool for understanding consumers’ preferences in relation to the formulation of health policy suggesting that in many circumstances, it is to be preferred to traditional quantitative methods as an evaluation technique.

PHARMACOECONOMICS INTRODUCTION IN THE CREATION OF POSITIVE DRUG LIST IN BULGARIA

Petrova GI GIP1, Benisheva TVB2, Ivanova AD1
1Faculty of Pharmacy, Sofia, Bulgaria; 2Ministry of Health, Sofia, Bulgaria

OBJECTIVES: To analyze the effect of the introduction of pharmacoeconomics evaluations in the creation of a positive drug list in Bulgaria. METHODS: Legislation analysis of the current regulation for the creation of positive drug lists and its impact on the number of medicines proposed for reimbursement and included in the list. RESULTS: Regulation for the creation of positive drug lists was issued in 2002 in Bulgaria with the aim to establish clear criteria for the selection of medicines for the reimbursement practice and decrease the number of reimbursed drugs. The medicines were separated into three main classes—originators; medicines for which there is a therapeutic alternative but which have higher efficiency or less adverse drug events, and generic medicines. For the first two groups, producers were asked to prepare pharmacoeconomic evaluation following previously established form. Out of the 3500 dosage forms registered in the country as prescription medicines, 2852 dossies were submitted, of which 2477 dosage forms were included in the positive drug list (530 INN). Originators account for 63%, imported generics for 19% and domestic generics for 18%. Excluded medicines compose 45% originators, 20% imported generics, 18% domestic generics. In comparison with previously existing drug lists, the number of drugs did not decrease significantly. Main difficulties during the evaluation process were lack of pharmacoeconomics analysis within the country, lack of national pharmacoeconomic guidelines and changes in the companies pricing policy. CONCLUSIONS: The introduction of pharmacoeconomic evaluation during the process of the creation of a positive drug list in Bulgaria did not decrease the number of selected medicines but stimulate companies to start developing evaluations within the country.

MEDICINAL CANNABIS IN THE NETHERLANDS

Janse AFC, Breekveldt-Postma NS, Erkens JIA, Herings RMC

PHARMO Institute, Utrecht, The Netherlands

OBJECTIVES: In The Netherlands, cannabis has been available for medicinal purposes in pharmacies upon prescription by a medical doctor since September 2003. This research was done to study the characteristics of patients that start to use cannabis from pharmacies. METHODS: A national enquiry was started to identify all patients who were prescribed medicinal cannabis. Patients were contacted by their pharmacist to fill out a questionnaire. The questionnaire contained items about characteristics of patients; complaints and morbidity; use of cannabis; experiences with other cannabis products. Furthermore, history of drug use was collected. RESULTS: In total, 200 patients...
INTRODUCING THE ‘FOURTH HURDLE’ IN THE NEW EUROPEAN UNION MEMBER STATES: THE CASE OF HUNGARY

Gulkis L1, Bonez P2, Drummond MF3
1Budapest University of Economic Sciences and Public Administration, Budapest, Hungary; 2National Health Insurance Fund Administration, Budapest, Hungary; 3University of York, York, North Yorkshire, UK

OBJECTIVES: This paper outlines the current development of the “fourth hurdle” (i.e. requirement of effectiveness and cost-effectiveness data for drug coverage policy decisions) in one of the new European Union member states, describes the needs and discusses some issues that a given jurisdiction needs to consider prior to introducing the “fourth hurdle” for pharmaceuticals. RESULTS: The “fourth hurdle” is very relevant to the new member states since many existing drugs are unevaluated and many new, expensive drugs are becoming available. On the other hand, the existing resources for health technology assessment, including economic evaluation, are quite limited. CONCLUSIONS: The most important issue seems to be that the implementation of the “fourth hurdle” needs to be achieved in a way consistent with the limited resources for health economics analysis in the new member states. Specifically this means that, in setting priorities for drugs to be evaluated, additional criteria need to be applied. In particular, priority should be given to assessing drugs that have been evaluated in other countries, since this affords the opportunity to adapt existing studies or models to the situation of the new European Union member states. Opportunity exists to learn from experiences and mistakes in other countries and to find ways to make optimal use of evidence produced elsewhere and processes, which are already thoroughly tested. Given these restrictions, recommendations will be made on how to implement results of economic evaluation, using health economics as a tool to support reimbursement of medicines as a case study.